A recent study published in JAMA Dermatology suggests that nicotinamide, a derivative of vitamin B3, may play a role in reducing the incidence of non-melanoma skin cancers. The study, involving over 33,000 U.S. veterans, found that individuals who took nicotinamide experienced a 14% decrease in future skin cancer cases. Notably, the most significant benefits were observed in participants who began taking the supplement after their initial skin cancer diagnosis, with their risk of developing another cancer reduced by more than half.
This research builds on prior clinical trials that indicated nicotinamide’s potential in lowering new skin cancer occurrences. The recent findings provide stronger evidence by utilizing real-world data, validating earlier results from smaller studies. Dermatologists note that nicotinamide may enhance the skin's ability to repair DNA damage caused by UV exposure and improve immune response, thus potentially preventing the survival of damaged cells that can lead to cancer.
Despite these promising results, experts caution that nicotinamide should not replace traditional preventive measures against skin cancer. Sunscreen, protective clothing, and regular skin examinations are still considered the primary strategies for prevention. The study's retrospective nature and its demographic limitations—primarily older and male participants—suggest that further research is necessary to generalize the findings to broader populations.
Healthcare professionals recommend viewing nicotinamide as a complementary approach, particularly for high-risk individuals or those with a history of skin cancers. Consistent use, in conjunction with established preventive practices, may enhance overall skin health and cancer prevention.